CP-GEP Model Successful in Stratifying Node-Negative Patients into Risk Groups for Melanoma Disease Progression
Source: Dermatology Times, April 2024
According to 2 studies, this model has demonstrated the potential to assist in developing treatment and monitoring plans for early-stage melanomas.
SkylineDx, a biotech company headquartered in Rotterdam, Netherlands, with a presence in San Diego, California, recently announced the publication of 2 scientific publications supporting the success of the company’s Merlin test, or CP-GEP model, in stratifying patients with early-stage cutaneous melanoma for risk and long-term survival.
The individual publications were revealed at the 20th European Association for Dermato-Oncology Congress, which ran from April 4 to 6 in Paris, France.